RetinalGenix Technologies Appoints Dr. Taimour Langaee as Advisor

RetinalGenix Technologies Inc., a pioneering company in advanced retinal imaging and precision medicine, has announced the appointment of Dr. Taimour Langaee, MSPH, PhD, as its new scientific advisor. This strategic decision, made public on June 13, 2025, emphasizes the company's commitment to integrating cutting-edge advancements in genomics and personalized medicine into its product pipeline, particularly its DNA GPS Pharmacogenetics initiatives, which aim to enhance personalized treatment pathways for retinal and systemic diseases.

Dr. Langaee, who serves as a Professor in the Department of Pharmacotherapeutics and Clinical Research at the University of South Florida’s Taneja College of Pharmacy, brings over 20 years of expertise in pharmacogenomics, genetics, and molecular biology. His extensive background includes leadership roles in significant research initiatives, such as the NIH Warfarin Study (COAG Trial) and various pharmacogenomic studies addressing cardiovascular, infectious, and neurological diseases. His past contributions at the University of Florida as the director of the Center for Pharmacogenomics and Precision Medicine Genotyping Core Laboratory further reinforce his qualifications in the field of precision medicine.

In his new role at RetinalGenix, Dr. Langaee will oversee the processing of genotyping and sequencing data, conduct genetic and pharmacogenomics data analyses, and lead clinical genetic association studies linking eye diseases to genetic variations. Jerry Katzman, MD, CEO of RetinalGenix Technologies, expressed enthusiasm about Dr. Langaee's appointment, noting that his expertise will be crucial as the company expands its DNA GPS initiatives. Katzman stated, "Dr. Langaee’s leadership in translating genetic insights into actionable clinical strategies aligns perfectly with our mission to deliver personalized, data-driven solutions for retinal and systemic health."

The appointment comes at a time when the integration of genomics into clinical practice is becoming increasingly crucial for improving drug safety and efficacy. Advanced retinal imaging technologies developed by RetinalGenix aim to identify early signs of chronic diseases, including diabetes, hypertension, and neurodegenerative disorders such as Alzheimer’s disease. Through the integration of high-resolution retinal imaging and genetic analysis, the company seeks to flag early warning signs of these conditions, thereby enabling timely interventions that can significantly enhance patient outcomes.

As Dr. Langaee joins the team, RetinalGenix continues to focus on innovative solutions at the intersection of retinal imaging, genetic analysis, and artificial intelligence. The company aims to revolutionize early disease detection and improve patient outcomes across multiple disease areas by developing proprietary technologies, including the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™.

Looking ahead, the integration of pharmacogenetics with retinal imaging holds promise for personalizing risk assessments and treatment plans based on individual genetic profiles. This could lead to more effective preventive strategies tailored to each patient's unique risk factors, ultimately maximizing the impact of interventions on overall health management.

In summary, Dr. Taimour Langaee’s appointment underscores RetinalGenix Technologies’ commitment to advancing precision medicine through innovative genomic approaches, positioning the company to address the complexities of both ocular and systemic health in the 21st century. As the landscape of personalized medicine evolves, the contributions of experts like Dr. Langaee will be pivotal in shaping the future of healthcare delivery and patient care in retinal and systemic disease management.